Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors.

ABSTRACT: The therapeutic landscape for patients with advanced malignancies has changed dramatically over the last twenty years. The growing number of targeted therapies and immunotherapeutic options available have improved response rates and survival for a subset of patients, however determining which patients will experience clinical benefit from these therapies in order to avoid potential toxicities and reduce healthcare costs remains a clinical challenge. Cell-free circulating tumor DNA (ctDNA) is shed by tumor cells into systemic circulation and is already an integral part of routine clinical practice for the non-invasive tumor genotyping in advanced non-small cell lung cancer as well as other malignancies. The short half-life of ctDNA offers a unique opportunity to utilize early on-treatment c

SUBMITTER: Thompson JC 

PROVIDER: S-EPMC10703899 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature